Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Anna Dąbrowska‐Iwanicka

First‐line R‐CVP Versus R‐CHOP Induction Immunochemotherapy for Indolent Lymphoma With Rituximab Maintenance. A Multicentre, Phase III Randomized Study by the Polish Lymphoma Research Group PLRG4

British Journal of Haematology

Hematology

2019

English

Related publications

Differences in Quality of Life Between Bendamustine-Rituximab and R-Chop/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Clinical Lymphoma, Myeloma and Leukemia

English

Rituximab Maintenance for Patients With Diffuse Large B-Cell Lymphoma in First Complete Remission: Results From a Randomized Hovon-Nordic Lymphoma Group Phase Iii Study

Hematological Oncology

English

ROBUST: First Report of Phase III Randomized Study of Lenalidomide/R-Chop (R2 -CHOP) vs Placebo/R-Chop in Previously Untreated ABC-type Diffuse Large B-Cell Lymphoma

Hematological Oncology

English

Da-Epoch-R Versus R-Chop in High Risk DLBCL Patients: Analysis of the Czech Lymphoma Study Group (Clsg)

Hematological Oncology

English

Robust: Phase Iii Randomized Study of Lenalidomide/R-Chop vs Placebo/R-Chop in Untreated Abc-Type Diffuse Large B-Cell Lymphoma and Feasibility of Cell of Origin Subtyping

Hematological Oncology

English

First-Line Treatment of Inhl or MCL Patients With Br or R-Chop/R-Cvp: Results of the Bright 5-Year Follow-Up Study

Hematological Oncology

English

Immunochemotherapy With Obinutuzumab or Rituximab in Previously Untreated Follicular Lymphoma in the Randomised Phase Iii Gallium Study: Analysis by Chemotherapy Regimen

Hematological Oncology

English

Bendamustine-Rituximab (Br) Versus R-Chop as Upfront Therapy for Indolent B-Cell Lymphomas: A Comparative, Population-Based Analysis

Hematological Oncology

English

Prospective Clinical Study of R-CMD Therapy for Indolent B Cell Lymphoma and Mantle Cell Lymphoma From the Hokuriku Hematology Oncology Study Group

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Anna Dąbrowska‐Iwanicka

First‐line R‐CVP Versus R‐CHOP Induction Immunochemotherapy for Indolent Lymphoma With Rituximab Maintenance. A Multicentre, Phase III Randomized Study by the Polish Lymphoma Research Group PLRG4

Related publications

Differences in Quality of Life Between Bendamustine-Rituximab and R-Chop/R-CVP in Patients With Previously Untreated Advanced Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Rituximab Maintenance for Patients With Diffuse Large B-Cell Lymphoma in First Complete Remission: Results From a Randomized Hovon-Nordic Lymphoma Group Phase Iii Study

ROBUST: First Report of Phase III Randomized Study of Lenalidomide/R-Chop (R2 -CHOP) vs Placebo/R-Chop in Previously Untreated ABC-type Diffuse Large B-Cell Lymphoma

Da-Epoch-R Versus R-Chop in High Risk DLBCL Patients: Analysis of the Czech Lymphoma Study Group (Clsg)

Robust: Phase Iii Randomized Study of Lenalidomide/R-Chop vs Placebo/R-Chop in Untreated Abc-Type Diffuse Large B-Cell Lymphoma and Feasibility of Cell of Origin Subtyping

First-Line Treatment of Inhl or MCL Patients With Br or R-Chop/R-Cvp: Results of the Bright 5-Year Follow-Up Study

Immunochemotherapy With Obinutuzumab or Rituximab in Previously Untreated Follicular Lymphoma in the Randomised Phase Iii Gallium Study: Analysis by Chemotherapy Regimen

Bendamustine-Rituximab (Br) Versus R-Chop as Upfront Therapy for Indolent B-Cell Lymphomas: A Comparative, Population-Based Analysis

Prospective Clinical Study of R-CMD Therapy for Indolent B Cell Lymphoma and Mantle Cell Lymphoma From the Hokuriku Hematology Oncology Study Group